AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
JPMorgan Upgrades Recursion Pharmaceuticals to Overweight on FAP Treatment Prospects
ByAinvest
Sunday, Jan 18, 2026 12:36 pm ET1min read
RXRX--
JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral, raising the price target to $11. The upgrade follows promising clinical trials for the MEK 1/2 inhibitor REC-4881 in Familial Adenomatous Polyposis (FAP) treatment. Estimated peak sales for REC-4881 are over $1 billion, with the company also working on REC-617, a CDK7 inhibitor for platinum-resistant ovarian cancer. The positive clinical trials support Recursion's long-term prospects, with over $400 million in milestone payments from pharmaceutical partnerships.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet